NEW YORK (TheStreet) -- DARA BioSciences (DARA) surged Monday after the company announced the FDA had granted Orphan Drug Designation to the company's experimental compound KRN5500 for the treatment of multiple myeloma.
The stock was up 26.74% to $1.42 at 10:50 a.m. More than 15.2 million shares had changed hands, which eclipsed the average volume of 748,475.
Must Read: Warren Buffett's 25 Favorite Stocks
DARA Price data by YCharts
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.